Vascular cognitive impairment and dementia (VCID) encompasses a heterogeneous group of disorders in which cerebrovascular pathology contributes to cognitive decline. Accumulating evidence from both clinical and basic studies suggests that neuroinflammation is one of the major mechanisms underlying VCID pathogenesis. However, its clinical evaluation remains challenging, and how it influences the process of VCID pathogenesis is still not fully understood. Experimental models of chronic cerebral hypoperfusion have demonstrated that decreased cerebral blood flow can activate innate immune responses and trigger inflammatory cascades. These cascades may contribute to white matter damage and cognitive deficits, and anti-inflammatory interventions have shown therapeutic potential in mitigating these outcomes. In this mini-review, we summarize recent findings on neuroinflammation from both clinical and basic studies, and discuss its role in VCID progression. A deeper understanding of the multifaceted mechanisms involved in inflammatory signaling will be essential for advancing VCID research and developing effective therapeutic strategies.
RundekTToleaMArikoT, et al. Vascular cognitive impairment (VCI). Neurotherapeutics2022; 19: 68–88.
2.
JellingerKA.Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci2013; 5: 17.
3.
GorelickPBScuteriABlackSE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2011; 42: 2672–2713.
4.
van der FlierWMSkoogISchneiderJA, et al. Vascular cognitive impairment. Nat Rev Dis Primers2018; 4: 18003.
5.
SnyderHMCorriveauRACraftS, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement2015; 11: 710–717.
6.
CorriveauRABosettiFEmrM, et al. The science of vascular contributions to cognitive impairment and dementia (VCID): a framework for advancing research priorities in the cerebrovascular biology of cognitive decline. Cell Mol Neurobiol2016; 36: 281–288.
7.
SachdevPKalariaRO’BrienJ, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord2014; 28: 206–218.
8.
BadjiAYouwakimJCooperA, et al. Vascular cognitive impairment—past, present, and future challenges. Ageing Res Rev2023; 90: 102042.
9.
VasCog-2–WSO Criteria Consortium; SachdevPSBentvelzenAC, et al. Revised diagnostic criteria for vascular cognitive impairment and dementia—the VasCog-2–WSO criteria. JAMA Neurol2025; 82: 1103–1112.
10.
FrantellizziVPaniARicciM, et al. Neuroimaging in vascular cognitive impairment and dementia: a systematic review. J Alzheimers Dis2020; 73: 1279–1294.
11.
van DintherMHooghiemstraAMBronEE, et al. Lower cerebral blood flow predicts cognitive decline in patients with vascular cognitive impairment. Alzheimers Dement2024; 20: 136–144.
12.
CopenWALevMHRapalinoO.Brain perfusion: computed tomography and magnetic resonance techniques. In: MasdeuJCGonzalezRG (eds.) Neuroimaging, Part I. Handbook of Clinical Neurology2016; 135: 117–135.
13.
StanimirovicDBFriedmanA.Pathophysiology of the neurovascular unit: disease cause or consequence?. J Cereb Blood Flow Metab2012; 32: 1207–1221.
14.
PohLSimWLJoD-G, et al. The role of inflammasomes in vascular cognitive impairment. Mol Neurodegener2022; 17: 4.
15.
ChenGYNuñezG.Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol2010; 10: 826–837.
16.
InabaTYamashiroKKuritaN, et al. Microbial lipopolysaccharide-induced inflammation contributes to cognitive impairment and white matter lesion progression in diet-induced obese mice with chronic cerebral hypoperfusion. CNS Neurosci Ther2023; 29: 200–212.
17.
del ZoppoGGinisIHallenbeckJM, et al. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol2000; 10: 95–112.
18.
KapasiALeurgansSArvanitakisZ, et al. β-Amyloid and tau tangle pathology modifies the association between small vessel disease and cortical microinfarcts. Stroke2021; 52: 1012–1021.
19.
VemuriPLesnickTGPrzybelskiSA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain2015; 138: 761–771.
20.
KimHJYangJJKwonH, et al. Relative impact of amyloid-β, lacunes, and downstream imaging markers on cognitive trajectories. Brain2016; 139: 2516–2527.
21.
CoomansEMvan WestenDBinetteAP, et al. Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation. Brain2024; 147: 949–960.
22.
AlexanderCLiTHattoriY, et al. Hypoxia inducible factor-1α binds and activates γ-secretase for Aβ production under hypoxia and cerebral hypoperfusion. Mol Psychiatry2022; 27: 4264–4273.
23.
WangNYangXZhaoZ, et al. Cooperation between neurovascular dysfunction and Aβ in Alzheimer’s disease. Front Mol Neurosci2023; 16: 1227493.
24.
ZhaoMJiangX-FZhangH-Q, et al. Interactions between glial cells and the blood–brain barrier and their role in Alzheimer’s disease. Ageing Res Rev2021; 72: 101483.
25.
FatimaGAshiquzzamanAKimSS, et al. Vascular and glymphatic dysfunction as drivers of cognitive impairment in Alzheimer’s disease: insights from computational approaches. Neurobiol Dis2025; 208: 106877.
26.
CrehanHHardyJPocockJ.Microglia, Alzheimer’s disease, and complement. Int J Alzheimers Dis2012; 2012: 983640.
27.
NizamiSHall-RobertsHWarrierS, et al. Microglial inflammation and phagocytosis in Alzheimer’s disease: potential therapeutic targets. Br J Pharmacol2019; 176: 3515–3532.
28.
Castro-GomezSHenekaMT.Innate immune activation in neurodegenerative diseases. Immunity2024; 57: 790–814.
29.
DengWGuoSvan VeluwSJ, et al. Effects of cerebral amyloid angiopathy on the brain vasculome. Aging Cell2022; 21: e13503.
30.
DiSabatoDJQuanNGodboutJP.Neuroinflammation: the devil is in the details. J Neurochem2016; 139: 136–153.
31.
EstesMLMcAllisterAK.Alterations in immune cells and mediators in the brain: it’s not always neuroinflammation!. Brain Pathol2014; 24: 623–630.
32.
ShaSTanJMiaoY, et al. The role of autophagy in hypoxia-induced neuroinflammation. DNA Cell Biol2021; 40: 733–739.
33.
Kölliker-FrersRUdovinLOtero-LosadaM, et al. Neuroinflammation: an integrating overview of reactive–neuroimmune cell interactions in health and disease. Mediators Inflamm2021; 2021: 9999146.
34.
McKenzieJASpielmanLJPointerCB, et al. Neuroinflammation as a common mechanism associated with the modifiable risk factors for Alzheimer’s and Parkinson’s diseases. Curr Aging Sci2017; 10: 158–176.
35.
NewtonKDixitVM.Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol2012; 4: a006049.
36.
Marín-TevaJLCuadrosMAMartín-OlivaD, et al. Microglia and neuronal cell death. Neuron Glia Biol2011; 7: 25–40.
37.
GrammasP.Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer’s disease. J Neuroinflammation2011; 8: 26.
38.
RossR.Atherosclerosis—an inflammatory disease. N Engl J Med1999; 340: 115–126.
39.
TianZJiXLiuJ.Neuroinflammation in vascular cognitive impairment and dementia: current evidence, advances, and prospects. Int J Mol Sci2022; 23: 6224.
40.
MillerRJRosteneWApartisE, et al. Chemokine action in the nervous system. J Neurosci2008; 28: 11792–11795.
41.
GinhouxFLimSHoeffelG, et al. Origin and differentiation of microglia. Front Cell Neurosci2013; 7: 45.
42.
FlarisNADensmoreTLMollestonMC, et al. Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia1993; 7: 34–40.
43.
HanischU-KKettenmannH.Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci2007; 10: 1387–1394.
44.
TianLMaLKaarelaT, et al. Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J Neuroinflammation2012; 9: 155.
45.
HooglandICMHouboltCvan WesterlooDJ, et al. Systemic inflammation and microglial activation: systematic review of animal experiments. J Neuroinflammation2015; 12: 114.
46.
RajanWDWojtasBGielniewskiB, et al. Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans. Neurobiol Dis2020; 137: 104722.
47.
PeknyMPeknaMMessingA, et al. Astrocytes: a central element in neurological diseases. Acta Neuropathol2016; 131: 323–345.
48.
PeferoenLKippMValkP, et al. Oligodendrocyte–microglia cross-talk in the central nervous system. Immunology2014; 141: 302–313.
49.
MaZZhangWWangC, et al. A new acquaintance of oligodendrocyte precursor cells in the central nervous system. Neurosci Bull2024; 40: 1573–1589.
50.
SeoJHMiyamotoNHayakawaK, et al. Oligodendrocyte precursors induce early blood–brain barrier opening after white matter injury. J Clin Invest2013; 123: 782–786.
51.
WoodLSingerAC.Neurons as immunomodulators: from rapid neural activity to prolonged regulation of cytokines and microglia. Annu Rev Biomed Eng2025; 27: 55–72.
52.
SheridanGKMurphyKJ.Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol2013; 3: 130181.
53.
LiuYWuX-MLuoQ-Q, et al. CX3CL1/CX3CR1-mediated microglia activation plays a detrimental role in ischemic mice brain via p38MAPK/PKC pathway. J Cereb Blood Flow Metab2015; 35: 1623–1631.
54.
VilcekJ.The cytokines: an overview. In: ThomsonAWLotzeMT (eds.) The cytokine handbook. Academic Press, 2003, pp.1–18.
55.
RameshGMacLeanAGPhilippMT.Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm2013; 2013: 480739.
56.
BenvenisteEN.Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol1992; 263: C1–C16.
57.
OlmosGLladóJ.Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm2014; 2014: 861231.
58.
WestPKViengkhouBCampbellIL, et al. Microglia responses to interleukin-6 and type I interferons in neuroinflammatory disease. Glia2019; 67: 1821–1841.
59.
MärzPHeeseKDimitriades-SchmutzB, et al. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia1999; 26: 191–200.
60.
ConductierGBlondeauNGuyonA, et al. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol2010; 224: 93–100.
61.
VeerhuisRNielsenHMTennerAJ.Complement in the brain. Mol Immunol2011; 48: 1592–1603.
62.
WoodruffTMAgerRRTennerAJ, et al. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med2010; 12: 179–192.
63.
BelkhelfaMBederNMouhoubD, et al. The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. J Neuroimmunol2018; 320: 48–57.
64.
SimpsonJEFernandoMSClarkL, et al. White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathol Appl Neurobiol2007; 33: 410–419.
65.
EngelhartMJGeerlingsMIMeijerJ, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol2004; 61: 668–672.
66.
SchmitzMHermannPOikonomouP, et al. Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy. Neurobiol Aging2015; 36: 2597–2606.
67.
ZulianiGRanziniMGuerraG, et al. Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res2007; 41: 686–693.
68.
DziedzicT.Systemic inflammatory markers and risk of dementia. Am J Alzheimers Dis Other Demen2006; 21: 258–262.
69.
KoyamaAO’BrienJWeuveJ, et al. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci2013; 68: 433–440.
70.
DarweeshSKLWoltersFJIkramMA, et al. Inflammatory markers and the risk of dementia and Alzheimer’s disease: a meta-analysis. Alzheimers Dement2018; 14: 1450–1459.
71.
CustoderoCCiavarellaAPanzaF, et al. Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. Geroscience2022; 44: 1373–1392.
72.
HuangWLiaoLLiuQ, et al. Blood biomarkers for vascular cognitive impairment based on neuronal function: a systematic review and meta-analysis. Front Neurol2025; 16: 1496711.
73.
TaoXHeJZhangY, et al. Fluid biomarkers of vascular cognitive impairment: from vascular pathophysiology to potential clinical applications. Neuroscience2025; 579: 267–283.
74.
HoshiTKitagawaKYamagamiH, et al. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke2005; 36: 768–772.
75.
van DijkEJPrinsNDVermeerSE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation2005; 112: 900–905.
76.
FassbenderKBertschTMielkeO, et al. Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke1999; 30: 1647–1650.
77.
HassanAHuntBJO’SullivanM, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain2003; 126: 424–432.
78.
KhreissTJózsefLPotempaLA, et al. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation2004; 109: 2016–2022.
79.
WallinAKapakiEBobanM, et al. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease—a consensus report. BMC Neurol2017; 17: 102.
80.
TarkowskiELiljerothAMMinthonL, et al. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull2003; 61: 255–260.
81.
BuchhavePZetterbergHBlennowK, et al. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging2010; 31: 1877–1884.
82.
Bonneh-BarkayDBisselSJWangG, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol2008; 173: 130–143.
83.
LlorensFSchmitzMKnipperT, et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease show different but partially overlapping profile compared to vascular dementia. Front Aging Neurosci2017; 9: 289.
84.
JanelidzeSHertzeJZetterbergH, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol2016; 3: 12–20.
85.
PeskindERGriffinWSAkamaKT, et al. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease. Neurochem Int2001; 39: 409–413.
86.
OlssonBHertzeJLautnerR, et al. Microglial markers are elevated in the prodromal phase of Alzheimer’s disease and vascular dementia. J Alzheimers Dis2013; 33: 45–53.
87.
BusseSHoffmannJMichlerE, et al. Dementia-associated changes of immune cell composition within the cerebrospinal fluid. Brain Behav Immun Health2021; 14: 100218.
88.
SchreiberSArndtPMortonL, et al. Immune system activation and cognitive impairment in arterial hypertension. Am J Physiol Cell Physiol2024; 327: C1577–C1590.
89.
TozerDJBrownRBWalshJ, et al. Do regions of increased inflammation progress to new white matter hyperintensities?: a longitudinal positron emission tomography–magnetic resonance imaging study. Stroke2023; 54: 549–557.
90.
WalshJTozerDJSariH, et al. Microglial activation and blood–brain barrier permeability in cerebral small vessel disease. Brain2021; 144: 1361–1371.
91.
LowAMakEMalpettiM, et al. In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer’s disease. J Neurol Neurosurg Psychiatry2021; 92: 45–52.
92.
HongHTozerDJChenY, et al. Perivascular space dysfunction in cerebral small vessel disease is related to neuroinflammation. Brain2025; 148: 1540–1550.
93.
EkenzeOPinheiroADemissieS, et al. Inflammatory biomarkers and MRI visible perivascular spaces: the Framingham Heart Study. Neurobiol Aging2023; 127: 12–22.
94.
ZouKDengQZhangH, et al. Glymphatic system: a gateway for neuroinflammation. Neural Regen Res2023; 19: 2661–2672.
95.
PengYSunYSongX, et al. Dual role of innate immune activation in cerebral small vessel disease. Int Immunopharmacol2025; 162: 115178.
96.
GoochJWilcockDM.Animal models of vascular cognitive impairment and dementia (VCID). Cell Mol Neurobiol2016; 36: 233–239.
97.
YuWLiYHuJ, et al. A study on the pathogenesis of vascular cognitive impairment and dementia: the chronic cerebral hypoperfusion hypothesis. J Clin Med2022; 11: 4742.
98.
IshikawaHShindoAMizutaniA, et al. A brief overview of a mouse model of cerebral hypoperfusion by bilateral carotid artery stenosis. J Cereb Blood Flow Metab2023; 43: 18–36.
99.
SagguRSchumacherTGerichF, et al. Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia. Acta Neuropathol Commun2016; 4: 76.
100.
DuanWGuiLZhouZ, et al. Adenosine A2A receptor deficiency exacerbates white matter lesions and cognitive deficits induced by chronic cerebral hypoperfusion in mice. J Neurol Sci2009; 285: 39–45.
101.
MiyamotoNPhamL-DDMakiT, et al. A radical scavenger edaravone inhibits matrix metalloproteinase-9 upregulation and blood–brain barrier breakdown in a mouse model of prolonged cerebral hypoperfusion. Neurosci Lett2014; 573: 40–45.
102.
YoshizakiKAdachiKKataokaS, et al. Chronic cerebral hypoperfusion induced by right unilateral common carotid artery occlusion causes delayed white matter lesions and cognitive impairment in adult mice. Exp Neurol2008; 210: 585–591.
103.
ZhouYZhangJWangL, et al. Interleukin-1β impedes oligodendrocyte progenitor cell recruitment and white matter repair following chronic cerebral hypoperfusion. Brain Behav Immun2017; 60: 93–105.
104.
MiyanoharaJKakaeMNagayasuK, et al. TRPM2 channel aggravates CNS inflammation and cognitive impairment via activation of microglia in chronic cerebral hypoperfusion. J Neurosci2018; 38: 3520–3533.
105.
HouXLiangXChenJ-F, et al. Ecto-5′-nucleotidase (CD73) is involved in chronic cerebral hypoperfusion-induced white matter lesions and cognitive impairment by regulating glial cell activation and pro-inflammatory cytokines. Neuroscience2015; 297: 118–126.
106.
ChengPZuoXRenY, et al. Adenosine A1-receptors modulate mTOR signaling to regulate white matter inflammatory lesions induced by chronic cerebral hypoperfusion. Neurochem Res2016; 41: 3272–3277.
107.
WangXLuZShaoQ, et al. Inhibition of 12/15-LOX hyperactivation mitigates cognitive decline in a chronic cerebral hypoperfusion mouse model and in H2O2-induced HT22 cells: therapeutic effects of brozopine. J Enzyme Inhib Med Chem2025; 40: 2547259.
108.
ChaiXLiXZhangW, et al. Legumain knockout improved cognitive impairment via reducing neuroinflammation in right unilateral common carotid artery occlusion mice. Life Sci2021; 285: 119944.
109.
WanY-SYouYDingQ-Y, et al. Triptolide protects against white matter injury induced by chronic cerebral hypoperfusion in mice. Acta Pharmacol Sin2022; 43: 15–25.
110.
HanQZhangHZhangX, et al. dl-3-n-Butylphthalide preserves white matter integrity and alleviates cognitive impairment in mice with chronic cerebral hypoperfusion. CNS Neurosci Ther2019; 25: 1042–1053.
111.
NakajiKIharaMTakahashiC, et al. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke2006; 37: 2816–2823.
112.
LinLChenYHeK, et al. Carotid artery vascular stenosis causes the blood–CSF barrier damage and neuroinflammation. J Neuroinflammation2024; 21: 220.
113.
LimY-ATanLSLeeWT, et al. Hope for vascular cognitive impairment: Ac-YVAD-cmk as a novel treatment against white matter rarefaction. PLoS One2024; 19: e0299703.
114.
BhatiaKKindelinANadeemM, et al. Complement C3a receptor (C3aR) mediates vascular dysfunction, hippocampal pathology, and cognitive impairment in a mouse model of VCID. Transl Stroke Res2022; 13: 816–829.
115.
ReimerMMMcQueenJSearcyL, et al. Rapid disruption of axon–glial integrity in response to mild cerebral hypoperfusion. J Neurosci2011; 31: 18185–18194.
116.
DietrichJ-B.The adhesion molecule ICAM-1 and its regulation in relation with the blood–brain barrier. J Neuroimmunol2002; 128: 58–68.
117.
HuangYZhangWLinL, et al. Is endothelial dysfunction of cerebral small vessel responsible for white matter lesions after chronic cerebral hypoperfusion in rats?. J Neurol Sci2010; 299: 72–80.
118.
WangYWuQFangY, et al. Depletion of regulatory T cells exacerbates inflammatory responses after chronic cerebral hypoperfusion in mice. Mol Cell Neurosci2022; 123: 103788.
119.
ZhangSWangYXieH, et al. Necroptosis and microglia activation after chronic ischemic brain injury in mice. Eur J Inflamm2017; 15: 78–84.
120.
JainMSinghMKShyamH, et al. Role of JAK/STAT in the neuroinflammation and its association with neurological disorders. Ann Neurosci2021; 28: 191–200.
121.
LiuQHeSGroysmanL, et al. White matter injury due to experimental chronic cerebral hypoperfusion is associated with C5 deposition. PLoS One2013; 8: e84802.
122.
ZhangL-YPanJMamtilahunM, et al. Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion. Theranostics2020; 10: 74–90.
123.
YuanBShiHZhengK, et al. MCP-1-mediated activation of microglia promotes white matter lesions and cognitive deficits by chronic cerebral hypoperfusion in mice. Mol Cell Neurosci2017; 78: 52–58.
124.
SchmidtRSchmidtHCurbJD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol2002; 52: 168–174.
125.
KellerMMazuchJAbrahamU, et al. A circadian clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci U S A2009; 106: 21407–21412.
126.
BoivinDBJamesFOWuA, et al. Circadian clock genes oscillate in human peripheral blood mononuclear cells. Blood2003; 102: 4143–4145.
127.
NakazatoRTakaradaTYamamotoT, et al. Selective upregulation of Per1 mRNA expression by ATP through activation of P2X7 purinergic receptors expressed in microglial cells. J Pharmacol Sci2011; 116: 350–361.
128.
FonkenLKFrankMGKittMM, et al. Microglia inflammatory responses are controlled by an intrinsic circadian clock. Brain Behav Immun2015; 45: 171–179.
129.
HayashiYKoyanagiSKusunoseN, et al. The intrinsic microglial molecular clock controls synaptic strength via the circadian expression of cathepsin S. Sci Rep2013; 3: 2744.
130.
MarpeganLSwanstromAEChungK, et al. Circadian regulation of ATP release in astrocytes. J Neurosci2011; 31: 8342–8350.
131.
MatteiDIvanovAHammerJ, et al. Microglia undergo molecular and functional adaptations to dark and light phases in male laboratory mice. Brain Behav Immun2024; 120: 571–583.
MengDYangMZhangH, et al. Microglia activation mediates circadian rhythm disruption-induced cognitive impairment in mice. J Neuroimmunol2023; 379: 578102.
134.
KawachiIColditzGAStampferMJ, et al. Prospective study of shift work and risk of coronary heart disease in women. Circulation1995; 92: 3178–3182.
135.
TüchsenFHannerzHBurrH.A 12 year prospective study of circulatory disease among Danish shift workers. Occup Environ Med2006; 63: 451–455.
136.
KarlssonBAlfredssonLKnutssonA, et al. Total mortality and cause-specific mortality of Swedish shift- and dayworkers in the pulp and paper industry in 1952–2001. Scand J Work Environ Health2005; 31: 30–35.
137.
VyasMVGargAXIansavichusAV, et al. Shift work and vascular events: systematic review and meta-analysis. BMJ2012; 345: e4800.
138.
TurinTCKitaYRumanaN, et al. Is there any circadian variation consequence on acute case fatality of stroke? Takashima Stroke Registry, Japan (1990–2003). Acta Neurol Scand2012; 125: 206–212.
139.
LiuJABumgarnerJRWalkerWH, et al. Chronic phase advances reduces recognition memory and increases vascular cognitive dementia-like impairments in aged mice. Sci Rep2024; 14: 7760.
140.
EarnestDJNeuendorffNCoffmanJ, et al. Sex differences in the impact of shift work schedules on pathological outcomes in an animal model of ischemic stroke. Endocrinology2016; 157: 2836–2843.
141.
FonkenLKBedrosianTAZhangN, et al. Dim light at night impairs recovery from global cerebral ischemia. Exp Neurol2019; 317: 100–109.
142.
Mee-IntaOZhaoZ-WKuoY-M.Physical exercise inhibits inflammation and microglial activation. Cells2019; 8: 691.
143.
SpielmanLJLittleJPKlegerisA.Physical activity and exercise attenuate neuroinflammation in neurological diseases. Brain Res Bull2016; 125: 19–29.
144.
KipEParr-BrownlieLC.Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. Front Neurosci2023; 17: 1092537.
145.
GubertCKongGRenoirT, et al. Exercise, diet and stress as modulators of gut microbiota: implications for neurodegenerative diseases. Neurobiol Dis2020; 134: 104621.
146.
JiangTZhangLPanX, et al. Physical exercise improves cognitive function together with microglia phenotype modulation and remyelination in chronic cerebral hypoperfusion. Front Cell Neurosci2017; 11: 404.
147.
OhtomoRKinoshitaKOhtomoG, et al. Treadmill exercise suppresses cognitive decline and increases white matter oligodendrocyte precursor cells in a mouse model of prolonged cerebral hypoperfusion. Transl Stroke Res2020; 11: 496–502.
148.
MillerAASpencerSJ.Obesity and neuroinflammation: a pathway to cognitive impairment. Brain Behav Immun2014; 42: 10–21.
149.
HagimoriRAbeMUenoR, et al. Microglial morphological changes and activation in chronic cerebral hypoperfusion are suppressed by lipid peroxidation inhibitor, methyldopa. J Neurochem2025; 169: e70287.
150.
KhanMBHodaMNVaibhavK, et al. Remote ischemic postconditioning: harnessing endogenous protection in a murine model of vascular cognitive impairment. Transl Stroke Res2015; 6: 69–77.
